Journal
CURRENT OPINION IN BIOMEDICAL ENGINEERING
Volume 10, Issue -, Pages 1-10Publisher
ELSEVIER
DOI: 10.1016/j.cobme.2018.12.004
Keywords
Biomaterial; Stem cell; Immunotherapy; Growth factors; Biomanufacturing
Categories
Funding
- National Institutes of Health [R01HL093282]
- National Institutes of Health (Biotechnology Training Program NIGMS) [5 T32-GM08349]
- Environmental Protection Agency (STAR Center) [83573701]
- National Science Foundation [DGE-1256259, DMR-1306482]
Ask authors/readers for more resources
Successful commercialization of cell-based therapies depends on technologies and processes that support scalable, reproducible, and economical cell biomanufacturing. Currently, derivation of target therapeutic cell types from primary cells and stem cells often involves lengthy expansion and differentiation processes that use substantial quantities of recombinant growth factors (GFs) and cytokines. Engineered biomaterials that can regulate GF delivery, activity, and signaling offer promise as tools to enable more efficient GF usage in cell culture. This review discusses emerging design strategies for GF-regulating biomaterials and how such materials may be applied to mitigate growth factor cost in cell biomanufacturing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available